Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Immunology Letters|August 19, 2008
Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargementOliver J Harrison, Joseph Foley, Brian J Bolognese, et al.
Obstetrics and Gynecology|November 1, 1976
Herpesvirus hominis type II infections in asymptomatic pregnant womenR J Bolognese, S L Corson, D A Fuccillo, et al.
The Journal of Reproductive Medicine|September 1, 1978
Cephradine and epicillin in body fluids of lactating and pregnant womenT W Mischler, S L Corson, A Larranaga, et al.
Obstetrics and Gynecology|September 1, 1987
Duplex Doppler ultrasound in the evaluation of growth in twin pregnanciesA G Gerson, D M Wallace, N K Bridgens, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 1998
Inhibitors of the p38 mitogen-activated kinase modulate IL-4 induction of low affinity IgE receptor (CD23) in human monocytesL A Marshall, M J Hansbury, B J Bolognese, et al.
Gastroenterology|September 29, 1999
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study GroupL Laine, S Harper, T Simon, et al.
Archives of Family Medicine|December 15, 2000
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies GroupK Saag, D van der Heijde, C Fisher, et al.
Aging (Milan, Italy)|June 19, 2001
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritisK E Truitt, R S Sperling, W H Ettinger, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 15, 1999
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study GroupM G Murphy, M A Bach, D Plotkin, et al.
Clinical Therapeutics|November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study GroupT J Schnitzer, K Truitt, R Fleischmann, et al.
Pageof 6